bevacizumab,panitumumab
amgen,roche,takeda
['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva']
 : new first-line combo in ras wild-type mcrc - panitumumab instead of bevacizumab with mfolfox6 results from phase 3 paradigm trial [#asco22 plenary lba1] . 
Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.